<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:35:44Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9079696" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9079696</identifier>
        <datestamp>2022-05-09</datestamp>
        <setSpec>redox</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Redox Biol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Redox Biol</journal-id>
              <journal-title-group>
                <journal-title>Redox Biology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2213-2317</issn>
              <publisher>
                <publisher-name>Elsevier</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9079696</article-id>
              <article-id pub-id-type="pmcid">PMC9079696</article-id>
              <article-id pub-id-type="pmc-uid">9079696</article-id>
              <article-id pub-id-type="pmid">35525024</article-id>
              <article-id pub-id-type="pii">S2213-2317(22)00090-8</article-id>
              <article-id pub-id-type="doi">10.1016/j.redox.2022.102318</article-id>
              <article-id pub-id-type="publisher-id">102318</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Paper</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au1">
                  <name>
                    <surname>Furqan</surname>
                    <given-names>Muhammad</given-names>
                  </name>
                  <email>muhammad-furqan@uiowa.edu</email>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="cor1" ref-type="corresp">∗</xref>
                </contrib>
                <contrib contrib-type="author" id="au2">
                  <name>
                    <surname>Abu-Hejleh</surname>
                    <given-names>Taher</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au3">
                  <name>
                    <surname>Stephens</surname>
                    <given-names>Laura M.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="au4">
                  <name>
                    <surname>Hartwig</surname>
                    <given-names>Stacey M.</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au5">
                  <name>
                    <surname>Mott</surname>
                    <given-names>Sarah L.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au6">
                  <name>
                    <surname>Pulliam</surname>
                    <given-names>Casey F.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au7">
                  <name>
                    <surname>Petronek</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au8">
                  <name>
                    <surname>Henrich</surname>
                    <given-names>John B.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au9">
                  <name>
                    <surname>Fath</surname>
                    <given-names>Melissa A.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au10">
                  <name>
                    <surname>Houtman</surname>
                    <given-names>Jon C.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff3" ref-type="aff">c</xref>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au11">
                  <name>
                    <surname>Varga</surname>
                    <given-names>Steven M.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff3" ref-type="aff">c</xref>
                  <xref rid="aff4" ref-type="aff">d</xref>
                  <xref rid="aff6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author" id="au12">
                  <name>
                    <surname>Bodeker</surname>
                    <given-names>Kellie L.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au13">
                  <name>
                    <surname>Bossler</surname>
                    <given-names>Aaron D.</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author" id="au14">
                  <name>
                    <surname>Bellizzi</surname>
                    <given-names>Andrew M.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author" id="au15">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Jun</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au16">
                  <name>
                    <surname>Monga</surname>
                    <given-names>Varun</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au17">
                  <name>
                    <surname>Mani</surname>
                    <given-names>Hariharasudan</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au18">
                  <name>
                    <surname>Ivanovic</surname>
                    <given-names>Marina</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author" id="au19">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Brian J.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff7" ref-type="aff">g</xref>
                </contrib>
                <contrib contrib-type="author" id="au20">
                  <name>
                    <surname>Byrne</surname>
                    <given-names>Margaret M.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au21">
                  <name>
                    <surname>Zeitler</surname>
                    <given-names>William</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au22">
                  <name>
                    <surname>Wagner</surname>
                    <given-names>Brett A.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au23">
                  <name>
                    <surname>Buettner</surname>
                    <given-names>Garry R.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au24">
                  <name>
                    <surname>Cullen</surname>
                    <given-names>Joseph J.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au25">
                  <name>
                    <surname>Buatti</surname>
                    <given-names>John M.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au26">
                  <name>
                    <surname>Spitz</surname>
                    <given-names>Douglas R.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au27">
                  <name>
                    <surname>Allen</surname>
                    <given-names>Bryan G.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <aff id="aff1"><label>a</label>Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA</aff>
                <aff id="aff2"><label>b</label>Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA</aff>
                <aff id="aff3"><label>c</label>Interdisciplinary Graduate Program in Immunology, University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA</aff>
                <aff id="aff4"><label>d</label>Department of Microbiology and Immunology, University of Iowa, 51 Newton Rd., Iowa City, IA, 52242, USA</aff>
                <aff id="aff5"><label>e</label>Department of Radiation Oncology, Free Radical and Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA</aff>
                <aff id="aff6"><label>f</label>Department of Pathology, University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA</aff>
                <aff id="aff7"><label>g</label>Department of Biostatistics, College of Public Health, University of Iowa, 145 N. Riverside Dr, Iowa City, IA, 52242, USA</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>∗</label>Corresponding author. Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, C21-K GH, Iowa City, IA, 52242, USA. <email>muhammad-furqan@uiowa.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>20</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="collection">
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <volume>53</volume>
              <elocation-id>102318</elocation-id>
              <history>
                <date date-type="received">
                  <day>15</day>
                  <month>2</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd">
                  <day>5</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>17</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 The Authors</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
                </license>
              </permissions>
              <abstract id="abs0010">
                <sec>
                  <title>Purpose</title>
                  <p>Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration. Pre-clinical studies have reported that pharmacological ascorbate (P-AscH-) enhances NSCLC response to platinum-based therapy. We conducted a phase II clinical trial combining P-AscH- with carboplatin-paclitaxel chemotherapy.</p>
                </sec>
                <sec>
                  <title>Experimental design</title>
                  <p>Chemotherapy naïve advanced stage NSCLC patients received 75 g ascorbate twice per week intravenously with carboplatin and paclitaxel every three weeks for four cycles. The primary endpoint was to improve tumor response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 compared to the historical control of 20%. The trial was conducted as an optimal Simon's two-stage design. Blood samples were collected for exploratory analyses.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>The study enrolled 38 patients and met its primary endpoint with an objective response rate of 34.2% (p = 0.03). All were confirmed partial responses (cPR). The disease control rate was 84.2% (stable disease + cPR). Median progression-free and overall survival were 5.7 months and 12.8 months, respectively. Treatment-related adverse events (TRAE) included one grade 5 (neutropenic fever) and five grade 4 events (cytopenias). Cytokine and chemokine data suggest that the combination elicits an immune response. Immunophenotyping of peripheral blood mononuclear cells demonstrated an increase in effector CD8 T-cells in patients with a progression-free survival (PFS) ≥ 6 months.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>The addition of P-AscH- to platinum-based chemotherapy improved tumor response in advanced stage NSCLC. P-AscH- appears to alter the host immune response and needs further investigation as a potential adjuvant to immunotherapy.</p>
                </sec>
              </abstract>
              <abstract abstract-type="author-highlights" id="abs0015">
                <title>Highlights</title>
                <p>
                  <list list-type="simple" id="ulist0010">
                    <list-item id="u0010">
                      <label>•</label>
                      <p id="p0010">The study evaluated the efficacy of Pharmacological Ascorbate with platinum-based chemotherapy in advanced-stage NSCLC.</p>
                    </list-item>
                    <list-item id="u0015">
                      <label>•</label>
                      <p id="p0015">Pharmacological Ascorbate improved the response of NSCLC to platinum-doublet chemotherapy.</p>
                    </list-item>
                    <list-item id="u0020">
                      <label>•</label>
                      <p id="p0020">Cytokine and chemokines data suggest that protocol regimen elicited an immune response.</p>
                    </list-item>
                    <list-item id="u0025">
                      <label>•</label>
                      <p id="p0025">Patients with longer PFS had a greater fold increase in circulating activated effector CD8 T cells.</p>
                    </list-item>
                    <list-item id="u0030">
                      <label>•</label>
                      <p id="p0030">The combination of ascorbate and chemotherapy was safe and tolerable.</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <kwd-group id="kwrds0010">
                <title>Keywords</title>
                <kwd>Non-small cell</kwd>
                <kwd>Ascorbate</kwd>
                <kwd>Vitamin C</kwd>
                <kwd>Platinum</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="sec1">
              <label>1</label>
              <title>Introduction</title>
              <p id="p0035">Lung cancer is the leading cause of cancer-related death in the United States, accounting for more deaths annually than breast, prostate, and colorectal cancers combined. Non-small cell lung cancer (NSCLC) comprises 85% of new lung cancer cases. Unfortunately, most patients are diagnosed with advanced disease [<xref rid="bib1" ref-type="bibr">1</xref>]. Immunotherapy with or without a platinum-based doublet chemotherapy is considered a standard first-line treatment for most patients with advanced stage NSCLC lacking a molecular driver alteration [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>]. The benefit of anti programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) immunotherapy in advanced stage NSCLC correlates with PD-L1 expression on the tumor. Platinum-based chemotherapy therefore is the mainstay of treatment or the backbone of combination therapies for NSCLC patients lacking PD-L1 expression [<xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>]. Unfortunately, these patients often have poor outcomes, leaving a significant need to develop more effective and safe therapies.</p>
              <p id="p0040">Pharmacological ascorbate (P-AscH<sup>-</sup>, intravenous infusions resulting in millimolar concenteraion of ascorbate in plasma) is a potential adjunct to chemotherapy [<xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>]. P-AscH<sup>-</sup> is selectively toxic to NSCLC and relatively innocuous to non-malignant cells [<xref rid="bib9" ref-type="bibr">9</xref>]. P-AscH<sup>-</sup>‘s selective cancer cell toxicity is due to fundamental differences in oxidative metabolism; more specifically, iron metabolism between malignant and non-malignant cells [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. Malignant cells have increased steady-state levels of reactive oxygen species (<italic>e.g.</italic>, superoxide [O<sub>2</sub><sup>•-</sup>], hydrogen peroxide [H<sub>2</sub>O<sub>2</sub>]), which can react with iron-containing proteins (<italic>e.g.</italic>, iron-sulfur cluster proteins and ferritin) to release redox active iron. In the presence of P-AscH<sup>-</sup>, redox active ferric iron is reduced to ferrous iron, leading to the formation of H<sub>2</sub>O<sub>2</sub>. H<sub>2</sub>O<sub>2</sub> can be directly toxic to cells by oxidizing critical biomolecules or reacting with Fe<sup>2+</sup> to produce hydroxyl radicals (HO•) <italic>via</italic> Fenton chemistry. HO• can damage proteins, lipids, and DNA, leading to platinum-chemotherapy sensitization. Non-malignant cells have lower endogenous levels of redox active iron, H<sub>2</sub>O<sub>2</sub>, and O<sub>2</sub><sup>•-</sup>, leading to less H<sub>2</sub>O<sub>2</sub> generated following P-AscH<sup>-</sup> treatment.</p>
              <p id="p0045">Pre-clinical <italic>in vitro</italic> and <italic>in vivo</italic> studies have shown that P-AscH<sup>-</sup> sensitizes a variety of solid tumors to chemotherapy and radiation [<xref rid="bib9" ref-type="bibr">9</xref>]. In early phase clinical trials P-AscH<sup>-</sup> has been evaluated with concurrent temozolamide and radiation in patients with glioblastoma, with gemcitabine in locally advanced stage pancreatic cancer, and with carboplatin-paclitaxel in ovarian cancers. No dose-limiting toxicities were observed in these trials [<xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>]. Treatment-related adverse events (TRAE) were similar to the expected toxicity profile associated with standard anti-cancer therapies alone. Moreover, in these early phase, single arm studies subject outcomes were superior to historical controls.</p>
              <p id="p0050">Based on its ability to enhance the cytotoxic effects of chemotherapy and the safety profile, P-AscH<sup>-</sup> is a promising adjunct therapy to platinum chemotherapy in patients with advanced NSCLC. This phase II trial explored the efficacy and safety of the combination of P-AscH<sup>-</sup> with carboplatin and paclitaxel in chemotherapy-naïve patients with advanced-stage NSCLC (NCT02420314).</p>
            </sec>
            <sec id="sec2">
              <label>2</label>
              <title>Materials and methods</title>
              <sec id="sec2.1">
                <label>2.1</label>
                <title>Patient selection</title>
                <p id="p0055">This open-label, single-arm, non-randomized phase II study, enrolled patients aged 18 years or older with pathologically-confirmed recurrent or stage IV NSCLC who had not received prior systemic therapy for advanced stage disease. Additional criteria for recruitment included an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and adequate hematologic, hepatic, and renal function. Patients with a known alteration in <italic>EGFR</italic> or <italic>ALK</italic> were allowed to enroll after progression on an approved tyrosine kinase inhibitor. Patients with treated brain metastases were also allowed to participate. Exclusion criteria included the presence of active hemoptysis, leptomeningeal disease, or glucose-6-phosphate-dehydrogenase deficiency. In December 2016, the protocol was modified to allow patients with PD-L1 tumor proportion score (TPS) ≥50% to enroll in the trial after progression on immunotherapy.</p>
              </sec>
              <sec id="sec2.2">
                <label>2.2</label>
                <title>Treatment</title>
                <p id="p0060">Eligible participants were planned to receive 75 g ascorbate intravenously twice per week for 12 weeks in combination with carboplatin (AUC 6) and paclitaxel (200 mg/m<sup>2</sup>) every three weeks for 4 cycles. Chemotherapy dose modifications were allowed for toxicity as per established standards. Ascorbate infusions were administered at a fixed dose. After completing four cycles (C) of chemotherapy, patients without progressive disease could receive maintenance or consolidation therapy at the discretion of the treating provider.</p>
              </sec>
              <sec id="sec2.3">
                <label>2.3</label>
                <title>Study objectives</title>
                <p id="p0065">The primary objective of the study was tumor response rate per RECIST v1.1. Tumor assessments were performed after chemotherapy cycles two and four. Participants who achieved partial or complete response underwent confirmatory tumor assessment ≥4 weeks following the initial imaging demonstrating the response. Patients with a partial response (PR) or stable disease (SD) were followed for disease progression (DP) and survival as per standard of care unless they withdrew consent. Secondary endpoints included progression-free survival (PFS), progression-free survival 2 (PFS2), overall survival (OS), and safety. All participants who received P-AscH<sup>-</sup> per protocol were included in the safety analysis. Adverse events (AEs) were graded per Common Terminology Criteria for Adverse Events (CTCAE) v4.03. After a protocol modification, patient-reported outcome measures were added as an exploratory endpoint and assessed using various Functional Assessment of Cancer Therapy (FACT) scales and subscales.</p>
              </sec>
              <sec id="sec2.4">
                <label>2.4</label>
                <title>Biomarkers analysis</title>
                <p id="p0070">PD-L1 expression was evaluated by immunohistochemistry with 22C3 (Dako, Carpinteria, CA) or E1L3N (Dako Autostainer Link 48) assays. Somatic alterations including substitutions, small deletions and insertions, copy number changes, and microsatellite instability was performed using Ampliseq-based next generation sequencing (NGS) with a 213 gene custom panel on a NextSeq 550 (Illumina Inc., San Diego, CA). Evaluation for gene rearrangements was performed by testing fusion transcripts using the Comprehensive Thyroid Lung FusionPlex Panel (Invitae Corp., San Francisco, CA) on a MiSeq (Illumina, Inc.). All testing was performed at the Clinical Laboratory Improvement Amendments-certified molecular pathology laboratory at the University of Iowa.</p>
                <p id="p0075">Blood and serum samples were collected at baseline, before each chemotherapy cycle, and at follow-up (C4d21 ± 7d) for exploratory analysis. Laboratory studies included pre- and post-therapy serum iron, ferritin, transferrin, transferrin saturation, and total iron binding capacity (TIBC). Redox-active serum markers, including 4-hydroxy-2-nonenal (4HNE) modified proteins, 3-nitrotyrosine (3NT), protein carbonyl, cytokines, and chemokines were also evaluated pre- and post-therapy. Plasma ascorbate levels were measured once during each chemotherapy cycle within 15 min of ascorbate infusions. Serum 4HNE, 3NT, and protein carbonyl assays were performed as previously described [<xref rid="bib14" ref-type="bibr">14</xref>].</p>
                <p id="p0080">The levels of 38 cytokines and chemokines were determined using the LEGENDplex Human Cytokine Panel 2, LEGENDplex Human Th Cytokine Panel, and LEGENDplex Human Proinflammatory Chemokine Panel 2 (Biolegend, San Diego, CA). Serum samples were thawed and diluted 2-fold with assay buffer supplied by BioLegend. The multiplex cytokine assays were then performed in filter plates per manufacturer's protocol. The samples were transferred to flat-bottomed 96-well plates and cytokine levels were determined using a Cytek Aurora flow cytometer (Cytek Biosciences, Fremont, CA).</p>
                <p id="p0085">For immunophenotyping, fresh whole blood samples were lysed using 1x Vitalyse (CytoMedical Design Group, St. Paul, MN). Cells were stained for extracellular cell surface markers using antibodies for CD3 (OKT3; BioLegend), CD4 (RPA-T4; Thermo Fisher, Pittsburgh, PA), CD8 (RPA-T8; Thermo Fisher), CCR7 (G043H7; BioLegend), CD45RA (HI100; Thermo Fisher), CD38 (HIT2; Thermo Fisher), HLA-DR (L243; BioLegend), CD127 (A019D5; BioLegend), CD25 (BC96; Thermo Fisher), CCR4 (L291H4; BioLegend), CD19 (HIB19; Thermo Fisher), CD20 (2H7; Thermo Fisher), CD14 (61D3; Thermo Fisher), and CD16 (3G8; BioLegend) for 30 min at 4 °C. All cells were fixed with fix/lyse solution (eBioscience, San Diego, CA) for 10 min at room temperature. Cells were run on an LSRFortessa (BD Biosciences, San Jose, CA) and analyzed using FlowJo software (BD Biosciences). Immune cell populations were gated as follows: CD4 T cells (CD3<sup>+</sup>CD4<sup>+</sup>), CD8 T cells (CD3<sup>+</sup>CD8<sup>+</sup>), activated effector CD4 T cells (CD3<sup>+</sup>CD4<sup>+</sup>CCR7<sup>−</sup>CD45RA<sup>+</sup>CD38<sup>+</sup>HLA-DR<sup>+</sup>), activated effector CD8 T cells (CD3<sup>+</sup>CD8<sup>+</sup>CCR7<sup>−</sup>CD45RA<sup>+</sup>CD38<sup>+</sup>HLA-DR<sup>+</sup>), classical monocytes (CD3<sup>−</sup>CD19<sup>−</sup>CD20<sup>−</sup>HLA-DR<sup>+</sup>CD14<sup>+</sup>CD16<sup>−</sup>), intermediate monocytes (CD3<sup>−</sup>CD19<sup>−</sup>CD20<sup>−</sup>HLA-DR<sup>+</sup>CD14<sup>+</sup>CD16<sup>+</sup>), non-classical monocytes (CD3<sup>−</sup>CD19<sup>−</sup>CD20<sup>−</sup>HLA-DR<sup>+</sup>CD14<sup>+/−</sup>CD16<sup>+</sup>), regulatory T cells (CD3<sup>+</sup>CD4<sup>+</sup>CD127<sup>−</sup>CD25+CCR4<sup>+</sup>).</p>
              </sec>
              <sec id="sec2.5">
                <label>2.5</label>
                <title>Statistical methods</title>
                <p id="p0090">The primary objective of this phase II trial was to evaluate the anti-tumor activity of P-AscH<sup>-</sup> combined with platinum-chemotherapy by testing the null statistical hypothesis that the best overall response rate is &lt;20% [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib16" ref-type="bibr">16</xref>] versus the alternative that it is greater. The best overall response was defined as a confirmed complete or partial response. The trial was conducted as an optimal Simon's two-stage design with 80% power to detect a response rate of 40% with one-sided testing performed at the 10% level of significance. Sample size calculations required 17 patients to be enrolled in the first stage of the study with termination if three or fewer responded. Otherwise, an additional 20 patients were to be evaluated in the second stage. If 11 or more of the total 37 patients responded, the treatment would be deemed worthy of further investigation.</p>
                <p id="p0095">The primary statistical analysis focused on the best overall response rate estimated as a binomial proportion along with a one-sided 90% confidence interval computed with the methods of Koyama &amp; Chen [<xref rid="bib17" ref-type="bibr">17</xref>]. Secondary analyses focused on safety, duration of response (DOR), PFS, OS, and quality of life (QoL). TRAEs were summarized by type and grade, reporting the most severe grade per patient. DOR was defined as time from first documentation of response to date of DP. PFS was defined as time from study treatment initiation to date of first documentation of DP or death due to any cause. Among participants who progressed and subsequently initiated second-line therapy, PFS2 was defined as time from study treatment initiation to date of first documentation of DP after second-line therapy or death due to any cause. Participants were censored at date of last radiographic assessment for DP. OS was defined as time from study treatment initiation to death due to any cause. Participants who were still alive were censored at the last date they were known to be alive. Survival probabilities were estimated and plotted using Kaplan-Meier. Estimates along with 95% pointwise confidence intervals (CI) are reported. Changes in participant-reported QoL scores were calculated from baseline to each subsequent (cycle and day) assessment time point (C2D1, C3D1, C4D1, C4D15). Mean estimates and 95% CI for QoL changes were derived using linear mixed effects regression models to account for the longitudinally-correlated nature of repeated QoL assessments at unequal intervals between visits with a spatial power correlation structure. Correlative analyses evaluated the effect of laboratory pretreatment and fold change values with PFS using Cox regression models. Fold change values were included as time-dependent covariates. All statistical testing of secondary endpoints was two-sided and assessed for significance at the 5% level.</p>
              </sec>
              <sec id="sec2.6">
                <label>2.6</label>
                <title>Ethics and oversight</title>
                <p id="p0100">The protocol was submitted to the U.S. Food and Drug Administration under Investigational New Drug 105715 and registered to <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0010">ClinicalTrials.gov</ext-link> prior to enrollment of the first patient (NCT02420314). Approval was obtained from The University of Iowa Institutional Review Board (Biomedical IRB01; IRB 201211713). Informed written consent was obtained from each participant prior to receiving protocol-based therapy. The trial was conducted according to the Belmont Report, the United States Common Rule (45CFR§46), and the International Council on Harmonisation—Good Clinical Practice as adopted by U.S. Federal law. All investigators were GCP trained. The University of Iowa Holden Comprehensive Cancer Center Data and Safety Monitoring Committee (DSMC) reviewed all data for compliance to protocol and participant safety. Safety and annual reports regarding this trial were submitted as required (21CFR§312.23, §312.32).</p>
              </sec>
            </sec>
            <sec id="sec3">
              <label>3</label>
              <title>Results</title>
              <p id="p0105">Between April 2015 and November 2020, 54 participants consented and 40 were enrolled in the study. This period included a temporary recruitment pause for the prespecified interim futility analysis. Data cut-off was performed on August 31, 2021. Two participants were deemed unevaluable by the study investigators and University of Iowa DSMC (withdrawal of consent [<italic>n</italic> = 1], chemotherapy dose violation [<italic>n</italic> = 1]). All participants were included in safety analysis and 38 evaluable participants were included in the statistical analyses of the primary and secondary endpoints (<xref rid="appsec1" ref-type="sec">Supplementary Fig. 1</xref>).</p>
              <p id="p0110">Demographics and baseline characteristics of participants are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>. The median age was 63 years. Thirteen percent (<italic>n</italic> = 5) of participants had an ECOG PS of 2, 94.7% had metastatic disease including 31.6% with treated brain metastases. Due to insufficient tumor samples, PD-L1 status could not be assessed for seven participants. PD-L1 TPS of &lt;1% represented 61.3% (19/31) of participants while 9.7% had PD-L1 TPS ≥50%. Of the nine participants who enrolled in the study after May 2018 (coinciding with the release of KeyNote189 trial data), six had PD-L1 TPS &lt;1%, two received and progressed on immunotherapy before participation in the study, and one did not have sufficient tissue for PD-L1 evaluation. Tumor samples from 33 participants were evaluated for somatic alterations in cancer-related genes. Molecular data from six participants who received testing through commercial assays as part of their standard of care (Foundation One CDx® [<italic>n</italic> = 3]; Neogenomics® [<italic>n</italic> = 2]; and CLARIS® [<italic>n</italic> = 1]) was included in the analysis of exploratory outcomes. Tumor samples from the remaining participants (n = 27) were tested at the University of Iowa. Since different platforms were used for testing, the number of genes and exonal coverage evaluated differed based on the testing site (<xref rid="tbl1" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Patient demographics and baseline characteristics.</p></caption><alt-text id="alttext0055">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Level</th><th><italic>n</italic> = 38<xref rid="tbl1fna" ref-type="table-fn">a</xref></th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">Median (Min-Max)</td><td align="left">63 (45–74)</td></tr><tr><td rowspan="2" align="left">Gender</td><td align="left">F</td><td align="left">13 (34.2%)</td></tr><tr><td align="left">M</td><td align="left">25 (65.8%)</td></tr><tr><td rowspan="2" align="left">Race</td><td align="left">Asian</td><td align="left">2 (5.3%)</td></tr><tr><td align="left">White</td><td align="left">36 (94.7%)</td></tr><tr><td rowspan="2" align="left">Ethnicity</td><td align="left">Hispanic or Latino</td><td align="left">1 (2.6%)</td></tr><tr><td align="left">Non-Hispanic</td><td align="left">37 (97.4%)</td></tr><tr><td rowspan="2" align="left">Histology</td><td align="left">Adenocarcinoma</td><td align="left">25 (65.8%)</td></tr><tr><td align="left">Squamous Cell Carcinoma</td><td align="left">13 (34.2%)</td></tr><tr><td rowspan="2" align="left">ECOG Performance Status</td><td align="left">0–1</td><td align="left">33 (86.8%)</td></tr><tr><td align="left">2</td><td align="left">5 (13.2%)</td></tr><tr><td rowspan="3" align="left">Smoking Status</td><td align="left">Active</td><td align="left">20 (52.6%)</td></tr><tr><td align="left">Former</td><td align="left">14 (36.8%)</td></tr><tr><td align="left">Never</td><td align="left">4 (10.5%)</td></tr><tr><td align="left">Liver Metastasis</td><td align="left">Yes</td><td align="left">4 (10.5%)</td></tr><tr><td align="left">Brain Metastasis</td><td align="left">Yes</td><td align="left">12 (31.6%)</td></tr><tr><td align="left">Bone Metastasis</td><td align="left">Yes</td><td align="left">12 (31.6%)</td></tr><tr><td rowspan="3" align="left">Highest Stage (AJCC 8th)</td><td align="left">N3</td><td align="left">2 (5.3%)</td></tr><tr><td align="left">M1a-b</td><td align="left">19 (50.0%)</td></tr><tr><td align="left">M1c</td><td align="left">17 (44.7%)</td></tr><tr><td rowspan="3" align="left">PD-L1 TPS (<italic>n</italic> = 31)</td><td align="left">&lt;1%</td><td align="left">19 (61.3%)</td></tr><tr><td align="left">1–49%</td><td align="left">9 (29.0%)</td></tr><tr><td align="left">≥50%</td><td align="left">3 (9.7%)</td></tr><tr><td align="left">KRAS (<italic>n</italic> = 33)</td><td align="left">Positive</td><td align="left">9 (27.3%)</td></tr><tr><td align="left">STK11 (<italic>n</italic> = 31)</td><td align="left">Positive</td><td align="left">3 (9.7%)</td></tr><tr><td align="left">KEAP1 (<italic>n</italic> = 28)</td><td align="left">Positive</td><td align="left">1 (3.6%)</td></tr><tr><td align="left">NFE2L2 (<italic>n</italic> = 28)</td><td align="left">Positive</td><td align="left">2 (7.1%)</td></tr><tr><td rowspan="2" align="left">Received Immunotherapy prior to enrollment</td><td align="left">No</td><td align="left">35 (92.1%)</td></tr><tr><td align="left">Yes</td><td align="left">3 (7.9%)</td></tr><tr><td rowspan="4" align="left">Protocol Defined Cycles Completed</td><td align="left">1</td><td align="left">2 (5.3%)</td></tr><tr><td align="left">2</td><td align="left">2 (5.3%)</td></tr><tr><td align="left">3</td><td align="left">2 (5.3%)</td></tr><tr><td align="left">4</td><td align="left">32 (84.2%)</td></tr><tr><td rowspan="2" align="left">Received 2nd Line Therapy</td><td align="left">No</td><td align="left">11 (28.9%)</td></tr><tr><td align="left">Yes</td><td align="left">27 (71.1%)</td></tr><tr><td rowspan="3" align="left">Type of 2nd Line Therapy</td><td align="left">Chemoimmunotherapy</td><td align="left">4 (14.8%)</td></tr><tr><td align="left">Chemotherapy</td><td align="left">5 (18.5%)</td></tr><tr><td align="left">Immunotherapy</td><td align="left">18 (66.7%)</td></tr></tbody></table><table-wrap-foot><fn><p>ECOG, Eastern Cooperative Group; AJCC, American Joint Committee on Cancer; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Number of patients assessed for PD-L1 TPS, <italic>KRAS</italic>, <italic>STK11</italic>, <italic>KEEP1</italic>, <italic>NFE2L2</italic> status varies.</p></fn></table-wrap-foot></table-wrap></p>
              <p id="p0115">Thirteen of 38 (34.2%) participants achieved PR per RECISTv1.1; all were confirmed partial responses (cPR). Median duration of response was six months with a range of 2.8–57.2 months. One participant continues to have ongoing PR. Nineteen participants (50.0%) had SD while five (13.2%) developed DP as their best response. One patient died before an initial response assessment. Depth of response and change in the sum of target disease are shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>A in relation to participant and disease characteristics. <xref rid="fig1" ref-type="fig">Fig. 1</xref>B shows participants’ disease status over time.<fig id="fig1"><label>Fig. 1</label><caption><p>Investigator-assessed antitumor activity of protocol treatment. A) Waterfall plot with maximum percent change in target lesions from baseline, along with demographics, disease characteristics, and endpoints. B) Swimmers plot. OR, best overall response; PR, partial response; SD, stable disease; PD, progression of disease, ECOG, Eastern Cooperative Oncology Group; PD-L1; programmed death ligand 1; PFS, progression-free survival in months; PFS2, progression-free survival 2 in months; OS, overall survival in months, N, negative; P, positive.</p></caption><alt-text id="alttext0045">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p>
              <p id="p0120">Median PFS was 5.7 months (95% CI: 4.3–7.0; <xref rid="fig2" ref-type="fig">Fig. 2</xref>A). PFS in relation to PD-L1 TPS is shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>B. Median PFS2 (<italic>n</italic> = 27) for patients receiving second-line therapy was 10.7 months (95% CI: 6.7–13.7; <xref rid="fig2" ref-type="fig">Fig. 2</xref>C). Median OS was 12.8 months (95% CI: 8.7–21.7; <xref rid="fig2" ref-type="fig">Fig. 2</xref>D). PFS2 and OS with respect to PD-L1 expression are shown in <xref rid="appsec1" ref-type="sec">Supplementary Fig. 2</xref>.<fig id="fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier analysis of progression-free survival per RECIST version 1.1 A) progression-free survival by PD-L1 TPS. B) Progression-free survival 2. C) and overall survival (D). CI, confidence interval; PD-L1, programmed death ligand 1.</p></caption><alt-text id="alttext0050">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p>
              <p id="p0125">Patients with ECOG PS 2 (<italic>n</italic> = 5) did poorly, with none having an objective response. Median PFS and OS for these patients were 3.2 and 5.4 months, respectively (<xref rid="tbl2" ref-type="table">Table 2</xref>). PD-L1 TPS was 1–49% for 2 participants, &lt;1% for two participants, and tissue was not available for a remaining patient. Prevalence of <italic>STK11</italic> and <italic>KEAP/NFE2L2</italic> mutations was 1/3 (33%) and 1/3 (33%) in participants with ECOG PS 2 compared to 2/29 (6.9%) and 2/25 (8.0%), respectively, in participants with ECOG PS 0–1 (<xref rid="fig1" ref-type="fig">Fig. 1</xref>A).<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Demographics and disease characteristics in relation to outcomes.</p></caption><alt-text id="alttext0060">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Level</th><th>N</th><th>ORR (%)</th><th>PFS<xref rid="tbl2fna" ref-type="table-fn">a</xref></th><th>PFS2<sup>a</sup><xref rid="tbl2fnb" ref-type="table-fn">b</xref></th><th>OS<xref rid="tbl2fna" ref-type="table-fn">a</xref></th></tr></thead><tbody><tr><td rowspan="2" align="left">Age</td><td align="left">≤65</td><td align="left">27</td><td align="left">10 (37.0)</td><td align="left">6.0 (4.3–8.7)</td><td align="left">11.1 (7.0–15.3)</td><td align="left">15.5 (9.0–39.0)</td></tr><tr><td align="left">&gt;65</td><td align="left">11</td><td align="left">3 (27.3)</td><td align="left">5.5 (0.5–6.4)</td><td align="left">7.3 (2.1–13.6)</td><td align="left">7.5 (2.7–21.7)</td></tr><tr><td rowspan="2" align="left">Gender</td><td align="left">Female</td><td align="left">13</td><td align="left">6 (46.2)</td><td align="left">5.7 (2.8–7.9)</td><td align="left">12.4 (6.2-NR)</td><td align="left">21.7 (6.4-NR)</td></tr><tr><td align="left">Male</td><td align="left">25</td><td align="left">7 (28.0)</td><td align="left">5.7 (3.6–8.5)</td><td align="left">10.0 (6.6–15.1)</td><td align="left">11.8 (8.7–17.4)</td></tr><tr><td rowspan="2" align="left">Histology</td><td align="left">Adenocarcinoma</td><td align="left">25</td><td align="left">9 (36.0)</td><td align="left">7.8 (5.2–8.9)</td><td align="left">12.9 (7.0–40.6)</td><td align="left">21.7 (11.6–39.0)</td></tr><tr><td align="left">Squamous Cell Carcinoma</td><td align="left">13</td><td align="left">4 (30.8)</td><td align="left">4.4 (2.8–5.5)</td><td align="left">7.4 (6.2–11.1)</td><td align="left">8.7 (6.3–13.1)</td></tr><tr><td rowspan="2" align="left">ECOG performance status</td><td align="left">0–1</td><td align="left">33</td><td align="left">13 (39.4)</td><td align="left">6.4 (4.9–7.9)</td><td align="left">11.1 (8.0–15.1)</td><td align="left">13.9 (10.5–29.8)</td></tr><tr><td align="left">2</td><td align="left">5</td><td align="left">0 (0)</td><td align="left">3.2 (1.9–3.6)</td><td align="left">6.0 (5.2–7.0)</td><td align="left">5.4 (3.2–34.3)</td></tr><tr><td rowspan="3" align="left">Smoking status</td><td align="left">Active</td><td align="left">20</td><td align="left">4 (20.0)</td><td align="left">4.0 (2.8–6.4)</td><td align="left">8.0 (5.4–10.7)</td><td align="left">11.1 (5.4–17.4)</td></tr><tr><td align="left">Former</td><td align="left">14</td><td align="left">6 (42.9)</td><td align="left">7.4 (4.4–9.5)</td><td align="left">13.7 (6.2-NR)</td><td align="left">34.3 (6.4-NR)</td></tr><tr><td align="left">Never</td><td align="left">4</td><td align="left">3 (75.0)</td><td align="left">5.6 (4.6–9.5)</td><td align="left">8.9 (6.6–15.1)</td><td align="left">14.6 (7.1-NR)</td></tr><tr><td rowspan="2" align="left">Liver metastasis</td><td align="left">No</td><td align="left">34</td><td align="left">12 (35.3)</td><td align="left">5.9 (4.4–7.9)</td><td align="left">11.1 (7.4–13.7)</td><td align="left">12.8 (8.7–21.7)</td></tr><tr><td align="left">Yes</td><td align="left">4</td><td align="left">1 (25.0)</td><td align="left">1.6 (1.2–6.8)</td><td align="left">6.6 (2.1-NR)</td><td align="left">20.3 (2.7-NR)</td></tr><tr><td rowspan="2" align="left">Brain metastasis</td><td align="left">No</td><td align="left">26</td><td align="left">9 (34.6)</td><td align="left">6.2 (4.6–7.9)</td><td align="left">11.7 (7.4–15.1)</td><td align="left">13.5 (9.0–34.3)</td></tr><tr><td align="left">Yes</td><td align="left">12</td><td align="left">4 (33.3)</td><td align="left">3.3 (1.2–8.5)</td><td align="left">6.2 (2.1–8.1)</td><td align="left">9.0 (3.2–29.8)</td></tr><tr><td rowspan="2" align="left">Bone metastasis</td><td align="left">No</td><td align="left">26</td><td align="left">12 (46.2)</td><td align="left">6.2 (3.5–7.9)</td><td align="left">11.7 (6.7–15.1)</td><td align="left">14.7 (9.0–39.0)</td></tr><tr><td align="left">Yes</td><td align="left">12</td><td align="left">1 (8.3)</td><td align="left">5.2 (2.5–8.7)</td><td align="left">7.4 (5.4–15.3)</td><td align="left">10.2 (5.4–21.7)</td></tr><tr><td rowspan="3" align="left">Highest stage (AJCC 8th)</td><td align="left">N3</td><td align="left">2</td><td align="left">0 (0)</td><td align="left">4.0 (3.5–4.4)</td><td align="left">8.9 (6.7–11.1)</td><td align="left">10.8 (9.0–12.5)</td></tr><tr><td align="left">M1a-b</td><td align="left">19</td><td align="left">11 (57.9)</td><td align="left">7.0 (5.5–8.9)</td><td align="left">13.6 (8.0–15.3)</td><td align="left">21.4 (10.5–39.0)</td></tr><tr><td align="left">M1c</td><td align="left">17</td><td align="left">2 (11.8)</td><td align="left">3.6 (1.9–6.8)</td><td align="left">7.2 (5.4–42.1)</td><td align="left">8.7 (5.4–29.8)</td></tr><tr><td rowspan="3" align="left">PD-L1 TPS</td><td align="left">&lt;1</td><td align="left">19</td><td align="left">7 (36.8)</td><td align="left">6.4 (4.9–8.7)</td><td align="left">13.7 (6.6–40.6)</td><td align="left">13.1 (6.4–36.9)</td></tr><tr><td align="left">1–49</td><td align="left">9</td><td align="left">1 (11.1)</td><td align="left">3.6 (1.3–6.8)</td><td align="left">7.4 (5.4–11.1)</td><td align="left">11.8 (5.4–21.7)</td></tr><tr><td align="left">≥50</td><td align="left">3</td><td align="left">3 (100)</td><td align="left">9.5 (7.8-NR)</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td rowspan="2" align="left"><italic>KRAS</italic></td><td align="left">Positive</td><td align="left">9</td><td align="left">3 (33.3)</td><td align="left">7.9 (1.9–10.4)</td><td align="left">10.0 (5.2–15.1)</td><td align="left">34.3 (5.4-NR)</td></tr><tr><td align="left">Negative</td><td align="left">24</td><td align="left">9 (37.5)</td><td align="left">5.7 (4.4–7.0)</td><td align="left">11.1 (6.6–15.3)</td><td align="left">12.8 (7.1–21.7)</td></tr><tr><td rowspan="2" align="left"><italic>STK11</italic></td><td align="left">Positive</td><td align="left">3</td><td align="left">2 (66.7)</td><td align="left">8.9 (3.6–9.5)</td><td align="left">10.2 (5.4–15.1)</td><td align="left">11.6 (5.4-NR)</td></tr><tr><td align="left">Negative</td><td align="left">28</td><td align="left">10 (35.7)</td><td align="left">5.9 (4.6–7.0)</td><td align="left">10.9 (6.6–15.3)</td><td align="left">15.5 (7.5–34.3)</td></tr><tr><td rowspan="2" align="left"><italic>KEAP1</italic> or <italic>NFE2L2</italic></td><td align="left">Positive</td><td align="left">3</td><td align="left">1 (33.3)</td><td align="left">3.2 (1.3–5.5)</td><td align="left">6.2 (5.2–6.6)</td><td align="left">6.3 (5.4–7.5)</td></tr><tr><td align="left">Negative</td><td align="left">25</td><td align="left">10 (40.0)</td><td align="left">6.4 (5.2–8.7)</td><td align="left">12.9 (8.0–40.6)</td><td align="left">21.7 (11.6–39.0)</td></tr></tbody></table><table-wrap-foot><fn><p>PFS, progression-free survival; PFS2, progression-free survival 2; OS, overall survival; ECOG, Eastern Cooperative Group; PD-L1, programmed death ligand 1; TPS, tumor proportion score.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0015">Median (95% CI).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0020">Patients who received second-line treatment (n = 27).</p></fn></table-wrap-foot></table-wrap></p>
              <p id="p0130">P-AscH<sup>-</sup> -related grade 1-2 adverse events (AEs), which occurred in ≥5% of the population included: dry mouth (35.0%), nausea (22.5%), hyponatremia (15.0%), transient hypertension (tHTN; 10.0%), headaches (7.5%), dizziness (7.5%), arthralgia/myalgia (7.5%), chills (5.0%), anorexia/dysgeusia (5.0%), hypocalcemia (5.0%), hypokalemia (5.0%), hypomagnesemia (5.0%), hypotension (5.0%), injection site reaction (5.0%), and sensory neuropathy (5.0%). Grade 3 toxicities included tHTN (27.5%), nausea (2.5%), peripheral edema (2.5%), atrial fibrillation (2.5%), diarrhea (2.5%), and fatigue (2.5%). No grade 4–5 P-AscH<sup>-</sup> related AEs were noted (<xref rid="appsec1" ref-type="sec">Supplementary Table 1</xref>). Toxicities attributed to chemotherapy are shown in <xref rid="appsec1" ref-type="sec">Supplementary Table 2</xref>.</p>
              <p id="p0135">Average post-infusion plasma ascorbate concentration was 17.6 mM. Exploratory analysis assessing P-AscH<sup>-</sup>‘s impact on serum iron biomarkers, cytokines, chemokines and redox-species were correlated with PFS (<xref rid="tbl3" ref-type="table">Table 3</xref> and <xref rid="appsec1" ref-type="sec">Supplementary Figs. 3 and 4</xref>). P-AscH<sup>-</sup> caused transient changes in serum ferritin, iron, and transferrin saturation levels, whereas transferrin and TIBC were largely unaffected (<xref rid="appsec1" ref-type="sec">Supplementary Fig. 4</xref>). Changes during therapy in iron-related biomarkers did not correlate with outcomes, although higher pretreatment levels of transferrin and TIBC were associated with decreased risk of progression (p = 0.04 and p = 0.05, respectively, (<xref rid="tbl3" ref-type="table">Table 3)</xref>). Pretreatment serum oxidative-stress markers, including 4HNE modified proteins, 3NT and protein carbonyl content did not correlate with PFS (<xref rid="tbl3" ref-type="table">Table 3</xref>, <xref rid="appsec1" ref-type="sec">Supplementary Fig. 4</xref>). However, a higher fold changes in protein carbonyl content from baseline was associated with an increased risk of progression (HR 2.00, 95% CI:1.18–3.38; p = 0.01). Among the cytokines and chemokines analyses, higher pre-treatment serum levels of IL-6 (HR 2.15, p &lt; 0.01) and CXCL8 (HR 1.82, p &lt; 0.01) correlated negatively with PFS.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Cytokines, chemokines, iron-related biomarkers and redox species in relation to progression free survival.</p></caption><alt-text id="alttext0065">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th><hr/></th><th colspan="5">Pretreatment Only<hr/></th><th colspan="5">Fold Change from Pretreatment<hr/></th></tr><tr><th>Covariate</th><th>Units<xref rid="tbl3fna" ref-type="table-fn">a</xref></th><th>Hazard Ratio</th><th colspan="2">95% CI</th><th>p-value</th><th>Units<xref rid="tbl3fnb" ref-type="table-fn">b</xref></th><th>Hazard Ratio</th><th colspan="2">95% CI</th><th>p-value</th></tr></thead><tbody><tr><td align="left">CXCL8</td><td align="left">0.05</td><td align="left">1.82</td><td align="left">1.20</td><td align="left">2.74</td><td align="left"><bold>&lt;.01</bold></td><td align="left">0.20</td><td align="left">1.01</td><td align="left">0.85</td><td align="left">1.21</td><td align="left">0.88</td></tr><tr><td align="left">CXCL10</td><td align="left">0.09</td><td align="left">1.39</td><td align="left">0.96</td><td align="left">2.02</td><td align="left">0.08</td><td align="left">0.41</td><td align="left">0.77</td><td align="left">0.55</td><td align="left">1.08</td><td align="left">0.13</td></tr><tr><td align="left">CCL11</td><td align="left">0.03</td><td align="left">0.83</td><td align="left">0.58</td><td align="left">1.19</td><td align="left">0.31</td><td align="left">0.25</td><td align="left">1.11</td><td align="left">0.82</td><td align="left">1.50</td><td align="left">0.49</td></tr><tr><td align="left">CCL17</td><td align="left">0.30</td><td align="left">1.50</td><td align="left">0.93</td><td align="left">2.43</td><td align="left">0.10</td><td align="left">0.56</td><td align="left">1.15</td><td align="left">0.79</td><td align="left">1.66</td><td align="left">0.47</td></tr><tr><td align="left">CCL2</td><td align="left">0.16</td><td align="left">0.99</td><td align="left">0.67</td><td align="left">1.47</td><td align="left">0.98</td><td align="left">0.25</td><td align="left">1.00</td><td align="left">0.86</td><td align="left">1.16</td><td align="left">0.96</td></tr><tr><td align="left">CCL5</td><td align="left">6.29</td><td align="left">1.25</td><td align="left">0.85</td><td align="left">1.84</td><td align="left">0.26</td><td align="left">0.42</td><td align="left">0.81</td><td align="left">0.59</td><td align="left">1.13</td><td align="left">0.21</td></tr><tr><td align="left">CCL3</td><td align="left">0.06</td><td align="left">1.34</td><td align="left">0.85</td><td align="left">2.12</td><td align="left">0.21</td><td align="left">0.28</td><td align="left">1.11</td><td align="left">0.74</td><td align="left">1.69</td><td align="left">0.61</td></tr><tr><td align="left">CXCL9</td><td align="left">0.02</td><td align="left">1.15</td><td align="left">0.80</td><td align="left">1.66</td><td align="left">0.45</td><td align="left">0.52</td><td align="left">0.97</td><td align="left">0.66</td><td align="left">1.42</td><td align="left">0.88</td></tr><tr><td align="left">CXCL5</td><td align="left">0.15</td><td align="left">0.80</td><td align="left">0.55</td><td align="left">1.16</td><td align="left">0.24</td><td align="left">0.63</td><td align="left">1.00</td><td align="left">0.62</td><td align="left">1.60</td><td align="left">1.00</td></tr><tr><td align="left">CCL20</td><td align="left">0.02</td><td align="left">1.47</td><td align="left">0.96</td><td align="left">2.24</td><td align="left">0.08</td><td align="left">2.68</td><td align="left">1.33</td><td align="left">0.88</td><td align="left">2.01</td><td align="left">0.18</td></tr><tr><td align="left">CXCL1</td><td align="left">0.04</td><td align="left">1.30</td><td align="left">0.86</td><td align="left">1.96</td><td align="left">0.22</td><td align="left">0.30</td><td align="left">1.10</td><td align="left">0.94</td><td align="left">1.29</td><td align="left">0.22</td></tr><tr><td align="left">CXCL11</td><td align="left">0.05</td><td align="left">1.25</td><td align="left">0.85</td><td align="left">1.84</td><td align="left">0.26</td><td align="left">0.80</td><td align="left">1.23</td><td align="left">0.76</td><td align="left">1.98</td><td align="left">0.40</td></tr><tr><td align="left">IL-6</td><td align="left">0.18</td><td align="left">2.15</td><td align="left">1.29</td><td align="left">3.60</td><td align="left"><bold>&lt;.01</bold></td><td align="left">0.50</td><td align="left">1.14</td><td align="left">0.91</td><td align="left">1.43</td><td align="left">0.24</td></tr><tr><td align="left">IL-22</td><td align="left">0.01</td><td align="left">1.08</td><td align="left">0.76</td><td align="left">1.53</td><td align="left">0.68</td><td align="left">2.29</td><td align="left">1.31</td><td align="left">0.40</td><td align="left">4.25</td><td align="left">0.65</td></tr><tr><td align="left">IL-12</td><td align="left">0.91</td><td align="left">1.06</td><td align="left">0.74</td><td align="left">1.51</td><td align="left">0.76</td><td align="left">2.27</td><td align="left">1.07</td><td align="left">0.34</td><td align="left">3.38</td><td align="left">0.91</td></tr><tr><td align="left">Ferritin</td><td align="left">324.01</td><td align="left">1.51</td><td align="left">0.99</td><td align="left">2.29</td><td align="left">0.05</td><td align="left">1.71</td><td align="left">1.00</td><td align="left">0.81</td><td align="left">1.24</td><td align="left">1.00</td></tr><tr><td align="left">Iron</td><td align="left">36.40</td><td align="left">0.90</td><td align="left">0.61</td><td align="left">1.34</td><td align="left">0.61</td><td align="left">1.18</td><td align="left">1.10</td><td align="left">0.70</td><td align="left">1.72</td><td align="left">0.68</td></tr><tr><td align="left">Iron saturation</td><td align="left">9.61</td><td align="left">0.96</td><td align="left">0.65</td><td align="left">1.41</td><td align="left">0.83</td><td align="left">1.01</td><td align="left">1.05</td><td align="left">0.70</td><td align="left">1.56</td><td align="left">0.83</td></tr><tr><td align="left">Total iron binding capacity</td><td align="left">64.00</td><td align="left">0.65</td><td align="left">0.42</td><td align="left">0.99</td><td align="left"><bold>0.04</bold></td><td align="left">0.21</td><td align="left">1.11</td><td align="left">0.78</td><td align="left">1.57</td><td align="left">0.56</td></tr><tr><td align="left">Transferrin</td><td align="left">44.69</td><td align="left">0.64</td><td align="left">0.42</td><td align="left">0.99</td><td align="left"><bold>0.05</bold></td><td align="left">0.21</td><td align="left">1.10</td><td align="left">0.78</td><td align="left">1.57</td><td align="left">0.58</td></tr><tr><td align="left">Carbonyl</td><td align="left">1364.90</td><td align="left">1.24</td><td align="left">0.86</td><td align="left">1.80</td><td align="left">0.25</td><td align="left">0.25</td><td align="left">2.00</td><td align="left">1.18</td><td align="left">3.38</td><td align="left"><bold>0.01</bold></td></tr><tr><td align="left">4HNE</td><td align="left">0.07</td><td align="left">0.71</td><td align="left">0.47</td><td align="left">1.06</td><td align="left">0.09</td><td align="left">0.37</td><td align="left">0.96</td><td align="left">0.60</td><td align="left">1.55</td><td align="left">0.88</td></tr><tr><td align="left">3NT</td><td align="left">17.32</td><td align="left">1.02</td><td align="left">0.70</td><td align="left">1.49</td><td align="left">0.92</td><td align="left">1.83</td><td align="left">0.99</td><td align="left">0.75</td><td align="left">1.30</td><td align="left">0.94</td></tr></tbody></table><table-wrap-foot><fn><p>CI, confidence interval; 4HNE, 4-hydroxy-2-nonenal (4HNE) modified proteins; 3NT, 3-nitrotyrosine.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0025">Units reflect 1 SD of pre-treatment values.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0030">Units reflect 1 SD of C3D1 values.</p></fn></table-wrap-foot></table-wrap></p>
              <p id="p0140">Immunophenotyping of peripheral blood mononuclear cells (n = 8) demonstrated a mean fold increase in activated effector CD8 T cells of 4.2 in participants with PFS ≥6 months (<italic>n</italic> = 5) compared to 1.6 in patients with PFS &lt;6 months (<italic>n</italic> = 3). Changes in activated effector CD4 T cells, CD8 T cells, Tregs and different monocyte populations are shown in <xref rid="appsec1" ref-type="sec">Supplementary Table 3</xref> and <xref rid="appsec1" ref-type="sec">Supplementary Fig. 5</xref>.</p>
              <p id="p0145">We assessed patient reported outcomes in 19 participants. Findings from patient-reported outcomes demonstrate that P-AscH<sup>-</sup> did not adversely impact QoL. In addition, we did not observe a particular change in QoL with respect to therapeutic response (<xref rid="appsec1" ref-type="sec">Supplementary Table 4</xref>, <xref rid="appsec1" ref-type="sec">Supplementary Fig. 6</xref>).</p>
            </sec>
            <sec id="sec4">
              <label>4</label>
              <title>Discussion</title>
              <p id="p0150">Immunotherapy has transformed the management of patients with metastatic NSCLC. The standard of care for patients with stage IV NSCLC is immunotherapy with or without chemotherapy. Despite the changes in the NSCLC therapeutic landscape, the prognosis of patients lacking PD-L1 expression (30–35% of all advanced stage NSCLC patients) remains poor. Furthermore, patients who have an initial benefit from immunotherapy commonly develop acquired resistance to anti-PD1 or PD-L1 therapies. Finding effective and safe treatments for patients without PD-L1 expression and for patients who develop resistance to anti-PD1/PD-L1 therapies are critical unmet needs.</p>
              <p id="p0155">A few decades ago, vitamin C was identified as a potential anti-cancer therapeutic [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib19" ref-type="bibr">19</xref>]. However, milimolar concentrations of ascorbate are required for cytotoxic effects which can only be achived by intravenous administration. To our knowledge, this is the first study to evaluate the combination of P-AscH<sup>-</sup> with platinum-based chemotherapy in advanced stage NSCLC.</p>
              <p id="p0160">In this study, we found that the addition of P-AscH<sup>-</sup> to chemotherapy significantly improved tumor response rate compare to historical control. Response rates in participants with advanced stage NSCLC treated with carboplatin-paclitaxel chemotherapy in large randomized trials has varied between 15% and 25% [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib16" ref-type="bibr">16</xref>,<xref rid="bib20" ref-type="bibr">[20]</xref>, <xref rid="bib21" ref-type="bibr">[21]</xref>, <xref rid="bib22" ref-type="bibr">[22]</xref>]. Though the addition P-AscH<sup>-</sup> improved subject outcomes (34% response rate), response rates in recent trials evaluating the combination of immunotherapy with platinum-based doublet chemotherapy range from 37.1% to 58.9% [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>].. These trials enrolled subjects with an ECOG performance status of 0–1 and utilized different platinum-based regimens. In these trials, pemetrexed was prescribed for non-squmaous NSCLC whereas either paclitaxel or nab-paclitaxel was combined with the platinum agent for squamous NSCLC except for IMpower150. In IMpower150, the chemotherapy regimen was similar to our study (i.e. carboplatin-paclitaxel) with atezolizumab; this combination yielded a response rate of 40.6% with mPFS of 6.9 months. The approval of immunotherapy during study enrollement period influenced patient recruitment; the majority of participants in this trial had PD-L1 TPS &lt;1% or enrolled after progression on first-line immunotherapy. In addition, this study included patients with ECOG PS 2, who are typically excluded from clinical trials. Despite these poor prognostic factors, median PFS and OS were numerically greater in this study than in NSCLC patients receiving standard of care chemotherapy in recently reported studies [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib5" ref-type="bibr">5</xref>]. Moreover, median PFS for patients with PD-L1 TPS &lt;1% in our study was numerically similar to patients receiving immunotherapy in the KeyNote189, KeyNote407 and 9LA studies [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib5" ref-type="bibr">5</xref>]. The adverse event profile was similar to those expected from a platinum-containing chemotherapy doublet. Overall, this study suggests that the combination of P-AscH<sup>-</sup> and chemotherapy is both effective and safe for the treatment of advanced NSCLC. However, larger and randomized studies are required to confirm these findings.</p>
              <p id="p0165">We analyzed the relationship between somatic alterations in <italic>KEAP1</italic>, <italic>NFE2L2</italic>, and <italic>STK11</italic> with participant outcomes as these genes are generally associated with poor clinical outcomes. In addition, these genes play an important role in cellular redox-biology and metabolism. We sought to determine whether an increases in oxidative stress generated by P-AscH<sup>-</sup> could overcome the enabling effect of <italic>KEAP1</italic> and <italic>NFE2L2</italic> mutations in NSCLC. In our study, three of 28 subjects had <italic>KEAP1</italic> or <italic>NFE2L2</italic> alterations and a poor outcome (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B). While not powered to detect a difference in survival, our data suggest the addition of P-AscH<sup>-</sup> to carboplatin-paclitaxel does not provide an additional benefit. However, two of three subjects with <italic>STK11</italic> mutations achieved a PR and had a longer PFS than the median (<xref rid="tbl2" ref-type="table">Table 2</xref>, <xref rid="fig1" ref-type="fig">Fig. 1</xref>A).</p>
              <p id="p0170">Redox active metals such as iron have been suggested to be selectively elevated in cancer cells representing a therapeutic target for the development of novel therapeutics [<xref rid="bib23" ref-type="bibr">23</xref>]. P-AscH<sup>-</sup>‘s selective toxicity to lung cancer cells depends upon redox active iron pools within the cell [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib24" ref-type="bibr">24</xref>]. Our group previously demonstrated that resected NSCLC tissue has increased steady-state level of superoxide [O<sub>2</sub><sup>•-</sup>] and redox-active labile iron compared to adjacent normal lung tissue. Oxidation of ascorbate produces H<sub>2</sub>O<sub>2</sub> that reacts with the increased labile iron in cancer cells to mediate Fenton chemistry and cause oxidative damage to cellular macromolecules (i.e., DNA, protein, lipids). Furthermore, H<sub>2</sub>O<sub>2</sub> produced from ascorbate oxidation selectively increases cancer cell redox-active iron, partially by disrupting iron-sulfur clusters, further exacerbating the differences in labile iron pool available for oxidation reactions that mediate ascorbate toxicity.</p>
              <p id="p0175">The role of systemic iron in pharmacological ascorbate mediated anti-tumor activity is currently unclear. At natural, dietary plasma levels (&lt;200 μM), ascorbate stimulates iron absorption <italic>via</italic> ferroportin expression [<xref rid="bib25" ref-type="bibr">25</xref>] and is cabpable of altering serum iron markers. To evaluate the effect of P-AscH<sup>-</sup> on circulating iron markers, we observed changes in serum iron, ferritin and transferrin saturation during relative to baseline values. Increased baseline transferrin and total iron binding capacity (TIBC) were associated with decreased risk of progression (<xref rid="tbl3" ref-type="table">Table 3</xref>) and this may just reflect the overall intensity of inflammation in the body. Inflammatory states (<italic>e.g.</italic> metastatic tumors), in general, are associated with a lower level of transferrin and TIBC. In contrast, subjects with low tumor burden may have less systemic inflammation with minimal or no effect on transferrin levels, which may explain this finding. Further investigation is needed to better understand the relationship between P-AscH<sup>-</sup>-related changes in serum iron markers and its influence on malignant cells’ redox active-iron pools.</p>
              <p id="p0180">Both IL-6 and CXCL8 are associated with an increase in myeloid-derived suppressor and regulatory T cells in the tumor microenvironment, tumor-cell proliferation, tumor invasiveness, decreased antigen presentation, limited response to ICI, and poor prognosis [<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib27" ref-type="bibr">27</xref>]. Pre- and on-treatment levels of these cytokines were associated with poor outcome (<xref rid="tbl3" ref-type="table">Table 3</xref>), which may reflect participants’ disease burden as opposed to an effect of the therapeutic interventions. We did observe changes in other cytokines and chemokines. However, dissecting P-AscH<sup>-</sup>-related changes and their significance is challenging (<xref rid="appsec1" ref-type="sec">Supplementary Fig. 3</xref>). Immunophenotyping of PBMCs was performed in a limited number of participants to assess the impact of P-AscH<sup>-</sup> and/or chemotherapy on the host immune response. Interestingly, participants with longer PFS demonstrated a higher fold increase in circulating activated effector CD8 T cells (<xref rid="appsec1" ref-type="sec">Supplementary Fig. 5</xref>, <xref rid="appsec1" ref-type="sec">Supplementary Table 3</xref>), although it is unclear whether this was a direct effect of therapy or an indirect effect from a change in disease burden. Emerging data from an ongoing phase II trial in patients with stage III NSCLC trial that combines P-AscH<sup>-</sup> with ionizing radiation and carboplatin-paclitaxel (NCT02905591) suggests that P-AscH<sup>-</sup> may have direct immunomodulatory effects (unpublished results). We continue to investigate the relevance of these alterations in the distribution of various immune cell populations within the peripheral blood during treatment in the ongoing study.</p>
              <p id="p0185">Finally, preclinical studies have shown that P-AscH<sup>-</sup> stimulates dendritic cells to secrete IL-12, drive differentiation of naïve CD4 T cells into Th1 cells, and increases CD8 effector T cells [<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib29" ref-type="bibr">29</xref>]. P-AscH<sup>-</sup> enhances the expression of human endogenous retroviruses (HERVs) <italic>via</italic> demethylation, improves immune recognition of tumor cells, increases intratumoral infiltration of CD8 T cells, increases the cytotoxicity of immune cells, and acts synergistically with anti-PD1/PDL-1 treatment in lymphoma, breast, melanoma and colorectal cancer models [<xref rid="bib30" ref-type="bibr">30</xref>,<xref rid="bib31" ref-type="bibr">31</xref>]. These anti-cancer immunomodulatory effects of P-AscH<sup>-</sup> are tumor-agnostic and need further exploration in pre-clinical studies and early phase clinical trials combining P-AscH<sup>-</sup> with immunotherapy ± chemotherapy. The encouraging findings of this study and emerging data regarding the immunomodulatory role of P-AscH<sup>-</sup> are promising and warrant further investigation.</p>
            </sec>
            <sec id="sec5">
              <label>5</label>
              <title>Conclusions</title>
              <p id="p0190">Addition of P-AscH<sup>-</sup> to platinum-doublet chemotherapy in advanced stage NSCLC significantly improved tumor response rate compared to historical controls. P-AscH<sup>-</sup> affects serum iron biomarkers; however, this did not correlate with clinical outcome. P-AscH<sup>-</sup> or the combination of P-AscH<sup>-</sup> with chemotherapy elicited an immune response. These findings are intriguing and need further investigation in future studies.</p>
            </sec>
            <sec id="sec6">
              <title>Funding sources</title>
              <p id="p0195">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health, United States</institution></institution-wrap></funding-source>, <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000054</institution-id><institution>National Cancer Institute, United States</institution></institution-wrap></funding-source> (P30 CA086862, P01 CA217797, R50 CA243693, T32 CA078586), Institutional grant (Holden <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008308</institution-id><institution>Comprehensive Cancer Center</institution></institution-wrap></funding-source> PACT grant) and patient donations.</p>
            </sec>
            <sec sec-type="COI-statement">
              <title>Declaration of competing interest</title>
              <p id="p0200">M Furqan acts as a institutional principal investigator/sub-investigator at AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, Genmab, Elicio Therapeutics, Mirati, Amgen, Replimmune, Checkmate Pharmaceuticals, Gilead, GSK, Tesaro and Abbvie. On advisory board for Abbvie, Jazz Pharma, Mirati, Astra Zeneca. DR Spitz and BG Allen received research support from Galera and serve as consultant for Galera Therapeutics. All authors report no conflicts of interest.</p>
            </sec>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <label>1</label>
                <element-citation publication-type="other" id="sref1">
                  <article-title>National cancer Institute surveillance epidemiology and end results program</article-title>
                  <comment>Cancer Stat Facts: Lung and Bronchus Cancer [Available from:</comment>
                  <ext-link ext-link-type="uri" xlink:href="https://seer.cancer.gov/statfacts/html/lungb.html" id="intref0020">https://seer.cancer.gov/statfacts/html/lungb.html</ext-link>
                </element-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <element-citation publication-type="journal" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Paz-Ares</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Ciuleanu</surname>
                      <given-names>T.E.</given-names>
                    </name>
                    <name>
                      <surname>Cobo</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Schenker</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Zurawski</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Menezes</surname>
                      <given-names>J.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial</article-title>
                  <source>Lancet Oncol.</source>
                  <volume>22</volume>
                  <issue>2</issue>
                  <year>2021</year>
                  <fpage>198</fpage>
                  <lpage>211</lpage>
                  <pub-id pub-id-type="pmid">33476593</pub-id>
                </element-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <element-citation publication-type="journal" id="sref3">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Socinski</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Jotte</surname>
                      <given-names>R.M.</given-names>
                    </name>
                    <name>
                      <surname>Cappuzzo</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Orlandi</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Stroyakovskiy</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Nogami</surname>
                      <given-names>N.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Atezolizumab for fiirst-line treatment of metastatic nonsquamous NSCLC</article-title>
                  <source>N. Engl. J. Med.</source>
                  <volume>378</volume>
                  <issue>24</issue>
                  <year>2018</year>
                  <fpage>2288</fpage>
                  <lpage>2301</lpage>
                  <pub-id pub-id-type="pmid">29863955</pub-id>
                </element-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Paz-Ares</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Luft</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Vicente</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Tafreshi</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Gumus</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Mazieres</surname>
                      <given-names>J.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer</article-title>
                  <source>N. Engl. J. Med.</source>
                  <volume>379</volume>
                  <issue>21</issue>
                  <year>2018</year>
                  <fpage>2040</fpage>
                  <lpage>2051</lpage>
                  <pub-id pub-id-type="pmid">30280635</pub-id>
                </element-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <element-citation publication-type="journal" id="sref5">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gandhi</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez-Abreu</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Gadgeel</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Esteban</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Felip</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>De Angelis</surname>
                      <given-names>F.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer</article-title>
                  <source>N. Engl. J. Med.</source>
                  <volume>378</volume>
                  <issue>22</issue>
                  <year>2018</year>
                  <fpage>2078</fpage>
                  <lpage>2092</lpage>
                  <pub-id pub-id-type="pmid">29658856</pub-id>
                </element-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <element-citation publication-type="journal" id="sref6">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <name>
                      <surname>Espey</surname>
                      <given-names>M.G.</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>A.Y.</given-names>
                    </name>
                    <name>
                      <surname>Pooput</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Kirk</surname>
                      <given-names>K.L.</given-names>
                    </name>
                    <name>
                      <surname>Krishna</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice</article-title>
                  <source>Proc. Natl. Acad. Sci. U. S. A.</source>
                  <volume>105</volume>
                  <issue>32</issue>
                  <year>2008</year>
                  <fpage>11105</fpage>
                  <lpage>11109</lpage>
                  <pub-id pub-id-type="pmid">18678913</pub-id>
                </element-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <element-citation publication-type="journal" id="sref7">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <name>
                      <surname>Espey</surname>
                      <given-names>M.G.</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>A.Y.</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>J.H.</given-names>
                    </name>
                    <name>
                      <surname>Krishna</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Shacter</surname>
                      <given-names>E.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo</article-title>
                  <source>Proc. Natl. Acad. Sci. U. S. A.</source>
                  <volume>104</volume>
                  <issue>21</issue>
                  <year>2007</year>
                  <fpage>8749</fpage>
                  <lpage>8754</lpage>
                  <pub-id pub-id-type="pmid">17502596</pub-id>
                </element-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <element-citation publication-type="journal" id="sref8">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <name>
                      <surname>Espey</surname>
                      <given-names>M.G.</given-names>
                    </name>
                    <name>
                      <surname>Krishna</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>J.B.</given-names>
                    </name>
                    <name>
                      <surname>Corpe</surname>
                      <given-names>C.P.</given-names>
                    </name>
                    <name>
                      <surname>Buettner</surname>
                      <given-names>G.R.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues</article-title>
                  <source>Proc. Natl. Acad. Sci. U. S. A</source>
                  <volume>102</volume>
                  <issue>38</issue>
                  <year>2005</year>
                  <fpage>13604</fpage>
                  <lpage>13609</lpage>
                  <pub-id pub-id-type="pmid">16157892</pub-id>
                </element-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schoenfeld</surname>
                      <given-names>J.D.</given-names>
                    </name>
                    <name>
                      <surname>Sibenaller</surname>
                      <given-names>Z.A.</given-names>
                    </name>
                    <name>
                      <surname>Mapuskar</surname>
                      <given-names>K.A.</given-names>
                    </name>
                    <name>
                      <surname>Wagner</surname>
                      <given-names>B.A.</given-names>
                    </name>
                    <name>
                      <surname>Cramer-Morales</surname>
                      <given-names>K.L.</given-names>
                    </name>
                    <name>
                      <surname>Furqan</surname>
                      <given-names>M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>O2(-) and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate</article-title>
                  <source>Cancer Cell</source>
                  <volume>31</volume>
                  <issue>4</issue>
                  <year>2017</year>
                  <fpage>487</fpage>
                  <lpage>500</lpage>
                  <comment>e8</comment>
                  <pub-id pub-id-type="pmid">28366679</pub-id>
                </element-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <element-citation publication-type="journal" id="sref10">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mapuskar</surname>
                      <given-names>K.A.</given-names>
                    </name>
                    <name>
                      <surname>Flippo</surname>
                      <given-names>K.H.</given-names>
                    </name>
                    <name>
                      <surname>Schoenfeld</surname>
                      <given-names>J.D.</given-names>
                    </name>
                    <name>
                      <surname>Riley</surname>
                      <given-names>D.P.</given-names>
                    </name>
                    <name>
                      <surname>Strack</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hejleh</surname>
                      <given-names>T.A.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mitochondrial superoxide increases age-associated susceptibility of human dermal fibroblasts to radiation and chemotherapy</article-title>
                  <source>Cancer Res.</source>
                  <volume>77</volume>
                  <issue>18</issue>
                  <year>2017</year>
                  <fpage>5054</fpage>
                  <lpage>5067</lpage>
                  <pub-id pub-id-type="pmid">28765155</pub-id>
                </element-citation>
              </ref>
              <ref id="bib11">
                <label>11</label>
                <element-citation publication-type="journal" id="sref11">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Allen</surname>
                      <given-names>B.G.</given-names>
                    </name>
                    <name>
                      <surname>Bodeker</surname>
                      <given-names>K.L.</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Monga</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Sandhu</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hohl</surname>
                      <given-names>R.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>First-in-Human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma</article-title>
                  <source>Clin. Cancer Res. : Off. J. Am. Assoc. Canc. Res.</source>
                  <volume>25</volume>
                  <issue>22</issue>
                  <year>2019</year>
                  <fpage>6590</fpage>
                  <lpage>6597</lpage>
                </element-citation>
              </ref>
              <ref id="bib12">
                <label>12</label>
                <element-citation publication-type="journal" id="sref12">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ma</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Chapman</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Levine</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Polireddy</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Drisko</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Q.</given-names>
                    </name>
                  </person-group>
                  <article-title>High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy</article-title>
                  <source>Sci. Transl. Med.</source>
                  <volume>6</volume>
                  <issue>222</issue>
                  <year>2014</year>
                  <object-id pub-id-type="publisher-id">222ra18</object-id>
                </element-citation>
              </ref>
              <ref id="bib13">
                <label>13</label>
                <element-citation publication-type="journal" id="sref13">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Welsh</surname>
                      <given-names>J.L.</given-names>
                    </name>
                    <name>
                      <surname>Wagner</surname>
                      <given-names>B.A.</given-names>
                    </name>
                    <name>
                      <surname>van't Erve</surname>
                      <given-names>T.J.</given-names>
                    </name>
                    <name>
                      <surname>Zehr</surname>
                      <given-names>P.S.</given-names>
                    </name>
                    <name>
                      <surname>Berg</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Halfdanarson</surname>
                      <given-names>T.R.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial</article-title>
                  <source>Cancer Chemother. Pharmacol.</source>
                  <volume>71</volume>
                  <issue>3</issue>
                  <year>2013</year>
                  <fpage>765</fpage>
                  <lpage>775</lpage>
                  <pub-id pub-id-type="pmid">23381814</pub-id>
                </element-citation>
              </ref>
              <ref id="bib14">
                <label>14</label>
                <element-citation publication-type="journal" id="sref14">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zahra</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Fath</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Opat</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Mapuskar</surname>
                      <given-names>K.A.</given-names>
                    </name>
                    <name>
                      <surname>Bhatia</surname>
                      <given-names>S.K.</given-names>
                    </name>
                    <name>
                      <surname>Ma</surname>
                      <given-names>D.C.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Consuming a ketogenic diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: the university of Iowa experience of two phase 1 clinical trials</article-title>
                  <source>Radiat. Res.</source>
                  <volume>187</volume>
                  <issue>6</issue>
                  <year>2017</year>
                  <fpage>743</fpage>
                  <lpage>754</lpage>
                  <pub-id pub-id-type="pmid">28437190</pub-id>
                </element-citation>
              </ref>
              <ref id="bib15">
                <label>15</label>
                <element-citation publication-type="journal" id="sref15">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sandler</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Gray</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Perry</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Brahmer</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Schiller</surname>
                      <given-names>J.H.</given-names>
                    </name>
                    <name>
                      <surname>Dowlati</surname>
                      <given-names>A.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</article-title>
                  <source>N. Engl. J. Med.</source>
                  <volume>355</volume>
                  <issue>24</issue>
                  <year>2006</year>
                  <fpage>2542</fpage>
                  <lpage>2550</lpage>
                  <pub-id pub-id-type="pmid">17167137</pub-id>
                </element-citation>
              </ref>
              <ref id="bib16">
                <label>16</label>
                <element-citation publication-type="journal" id="sref16">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schiller</surname>
                      <given-names>J.H.</given-names>
                    </name>
                    <name>
                      <surname>Harrington</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Belani</surname>
                      <given-names>C.P.</given-names>
                    </name>
                    <name>
                      <surname>Langer</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Sandler</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Krook</surname>
                      <given-names>J.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</article-title>
                  <source>N. Engl. J. Med.</source>
                  <volume>346</volume>
                  <issue>2</issue>
                  <year>2002</year>
                  <fpage>92</fpage>
                  <lpage>98</lpage>
                  <pub-id pub-id-type="pmid">11784875</pub-id>
                </element-citation>
              </ref>
              <ref id="bib17">
                <label>17</label>
                <element-citation publication-type="journal" id="sref17">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koyama</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Proper inference from Simon's two-stage designs</article-title>
                  <source>Stat. Med.</source>
                  <volume>27</volume>
                  <issue>16</issue>
                  <year>2008</year>
                  <fpage>3145</fpage>
                  <lpage>3154</lpage>
                  <pub-id pub-id-type="pmid">17960777</pub-id>
                </element-citation>
              </ref>
              <ref id="bib18">
                <label>18</label>
                <element-citation publication-type="journal" id="sref18">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moertel</surname>
                      <given-names>C.G.</given-names>
                    </name>
                    <name>
                      <surname>Fleming</surname>
                      <given-names>T.R.</given-names>
                    </name>
                    <name>
                      <surname>Creagan</surname>
                      <given-names>E.T.</given-names>
                    </name>
                    <name>
                      <surname>Rubin</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>O'Connell</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Ames</surname>
                      <given-names>M.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison</article-title>
                  <source>N. Engl. J. Med.</source>
                  <volume>312</volume>
                  <issue>3</issue>
                  <year>1985</year>
                  <fpage>137</fpage>
                  <lpage>141</lpage>
                  <pub-id pub-id-type="pmid">3880867</pub-id>
                </element-citation>
              </ref>
              <ref id="bib19">
                <label>19</label>
                <element-citation publication-type="journal" id="sref19">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Creagan</surname>
                      <given-names>E.T.</given-names>
                    </name>
                    <name>
                      <surname>Moertel</surname>
                      <given-names>C.G.</given-names>
                    </name>
                    <name>
                      <surname>O'Fallon</surname>
                      <given-names>J.R.</given-names>
                    </name>
                    <name>
                      <surname>Schutt</surname>
                      <given-names>A.J.</given-names>
                    </name>
                    <name>
                      <surname>O'Connell</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Rubin</surname>
                      <given-names>J.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial</article-title>
                  <source>N. Engl. J. Med.</source>
                  <volume>301</volume>
                  <issue>13</issue>
                  <year>1979</year>
                  <fpage>687</fpage>
                  <lpage>690</lpage>
                  <pub-id pub-id-type="pmid">384241</pub-id>
                </element-citation>
              </ref>
              <ref id="bib20">
                <label>20</label>
                <element-citation publication-type="journal" id="sref20">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Socinski</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Bondarenko</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Karaseva</surname>
                      <given-names>N.A.</given-names>
                    </name>
                    <name>
                      <surname>Makhson</surname>
                      <given-names>A.M.</given-names>
                    </name>
                    <name>
                      <surname>Vynnychenko</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Okamoto</surname>
                      <given-names>I.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial</article-title>
                  <source>J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol.</source>
                  <volume>30</volume>
                  <issue>17</issue>
                  <year>2012</year>
                  <fpage>2055</fpage>
                  <lpage>2062</lpage>
                </element-citation>
              </ref>
              <ref id="bib21">
                <label>21</label>
                <element-citation publication-type="journal" id="sref21">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Belani</surname>
                      <given-names>C.P.</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>J.S.</given-names>
                    </name>
                    <name>
                      <surname>Socinski</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Robert</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Waterhouse</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Rowland</surname>
                      <given-names>K.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer</article-title>
                  <source>Ann. Oncol. : Off. J. European Soc. Med. Oncol. / ESMO</source>
                  <volume>16</volume>
                  <issue>7</issue>
                  <year>2005</year>
                  <fpage>1069</fpage>
                  <lpage>1075</lpage>
                </element-citation>
              </ref>
              <ref id="bib22">
                <label>22</label>
                <element-citation publication-type="journal" id="sref22">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rosell</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Gatzemeier</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Betticher</surname>
                      <given-names>D.C.</given-names>
                    </name>
                    <name>
                      <surname>Keppler</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Macha</surname>
                      <given-names>H.N.</given-names>
                    </name>
                    <name>
                      <surname>Pirker</surname>
                      <given-names>R.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial</article-title>
                  <source>Ann. Oncol. : Off. J. European Soc. Med. Oncol. / ESMO</source>
                  <volume>13</volume>
                  <issue>10</issue>
                  <year>2002</year>
                  <fpage>1539</fpage>
                  <lpage>1549</lpage>
                </element-citation>
              </ref>
              <ref id="bib23">
                <label>23</label>
                <element-citation publication-type="journal" id="sref23">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalinowski</surname>
                      <given-names>D.S.</given-names>
                    </name>
                    <name>
                      <surname>Stefani</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Toyokuni</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Ganz</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Anderson</surname>
                      <given-names>G.J.</given-names>
                    </name>
                    <name>
                      <surname>Subramaniam</surname>
                      <given-names>N.V.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Redox cycling metals: pedaling their roles in metabolism and their use in the development of novel therapeutics</article-title>
                  <source>Biochim. Biophys. Acta</source>
                  <volume>1863</volume>
                  <issue>4</issue>
                  <year>2016</year>
                  <fpage>727</fpage>
                  <lpage>748</lpage>
                  <pub-id pub-id-type="pmid">26844773</pub-id>
                </element-citation>
              </ref>
              <ref id="bib24">
                <label>24</label>
                <element-citation publication-type="journal" id="sref24">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhou</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Zhao</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Lv</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Shang</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Labile iron affects pharmacological ascorbate-induced toxicity in osteosarcoma cell lines</article-title>
                  <source>Free Radic. Res.</source>
                  <volume>54</volume>
                  <issue>6</issue>
                  <year>2020</year>
                  <fpage>385</fpage>
                  <lpage>396</lpage>
                  <pub-id pub-id-type="pmid">32183598</pub-id>
                </element-citation>
              </ref>
              <ref id="bib25">
                <label>25</label>
                <element-citation publication-type="journal" id="sref25">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scheers</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Sandberg</surname>
                      <given-names>A.S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Iron transport through ferroportin is induced by intracellular ascorbate and involves IRP2 and HIF2alpha</article-title>
                  <source>Nutrients</source>
                  <volume>6</volume>
                  <issue>1</issue>
                  <year>2014</year>
                  <fpage>249</fpage>
                  <lpage>260</lpage>
                  <pub-id pub-id-type="pmid">24394537</pub-id>
                </element-citation>
              </ref>
              <ref id="bib26">
                <label>26</label>
                <element-citation publication-type="journal" id="sref26">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bakouny</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Choueiri</surname>
                      <given-names>T.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>IL-8 and cancer prognosis on immunotherapy</article-title>
                  <source>Nat. Med.</source>
                  <volume>26</volume>
                  <issue>5</issue>
                  <year>2020</year>
                  <fpage>650</fpage>
                  <lpage>651</lpage>
                  <pub-id pub-id-type="pmid">32405061</pub-id>
                </element-citation>
              </ref>
              <ref id="bib27">
                <label>27</label>
                <element-citation publication-type="journal" id="sref27">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Johnson</surname>
                      <given-names>D.E.</given-names>
                    </name>
                    <name>
                      <surname>O'Keefe</surname>
                      <given-names>R.A.</given-names>
                    </name>
                    <name>
                      <surname>Grandis</surname>
                      <given-names>J.R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</article-title>
                  <source>Nat. Rev. Clin. Oncol.</source>
                  <volume>15</volume>
                  <issue>4</issue>
                  <year>2018</year>
                  <fpage>234</fpage>
                  <lpage>248</lpage>
                  <pub-id pub-id-type="pmid">29405201</pub-id>
                </element-citation>
              </ref>
              <ref id="bib28">
                <label>28</label>
                <element-citation publication-type="journal" id="sref28">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jeong</surname>
                      <given-names>Y.J.</given-names>
                    </name>
                    <name>
                      <surname>Hong</surname>
                      <given-names>S.W.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>J.H.</given-names>
                    </name>
                    <name>
                      <surname>Jin</surname>
                      <given-names>D.H.</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>J.S.</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>W.J.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Vitamin C-treated murine bone marrow-derived dendritic cells preferentially drive naive T cells into Th1 cells by increased IL-12 secretions</article-title>
                  <source>Cell. Immunol.</source>
                  <volume>266</volume>
                  <issue>2</issue>
                  <year>2011</year>
                  <fpage>192</fpage>
                  <lpage>199</lpage>
                  <pub-id pub-id-type="pmid">21074755</pub-id>
                </element-citation>
              </ref>
              <ref id="bib29">
                <label>29</label>
                <element-citation publication-type="journal" id="sref29">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jeong</surname>
                      <given-names>Y.J.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>J.H.</given-names>
                    </name>
                    <name>
                      <surname>Hong</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>J.S.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>H.R.</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>W.J.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Vitamin C treatment of mouse bone marrow-derived dendritic cells enhanced CD8(+) memory T cell production capacity of these cells in vivo</article-title>
                  <source>Immunobiology</source>
                  <volume>219</volume>
                  <issue>7</issue>
                  <year>2014</year>
                  <fpage>554</fpage>
                  <lpage>564</lpage>
                  <pub-id pub-id-type="pmid">24698552</pub-id>
                </element-citation>
              </ref>
              <ref id="bib30">
                <label>30</label>
                <element-citation publication-type="journal" id="sref30">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Luchtel</surname>
                      <given-names>R.A.</given-names>
                    </name>
                    <name>
                      <surname>Bhagat</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Pradhan</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Jacobs</surname>
                      <given-names>W.R.</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                    <name>
                      <surname>Levine</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Verma</surname>
                      <given-names>A.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model</article-title>
                  <source>Proc. Natl. Acad. Sci. U. S. A</source>
                  <volume>117</volume>
                  <issue>3</issue>
                  <year>2020</year>
                  <fpage>1666</fpage>
                  <lpage>1677</lpage>
                  <pub-id pub-id-type="pmid">31911474</pub-id>
                </element-citation>
              </ref>
              <ref id="bib31">
                <label>31</label>
                <element-citation publication-type="journal" id="sref31">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Magri</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Germano</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Lorenzato</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Lamba</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Chila</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Montone</surname>
                      <given-names>M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>High-dose vitamin C enhances cancer immunotherapy</article-title>
                  <source>Sci. Transl. Med.</source>
                  <volume>12</volume>
                  <issue>532</issue>
                  <year>2020</year>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="appsec1" sec-type="supplementary-material">
              <label>Appendix A</label>
              <title>Supplementary data</title>
              <p id="p0210">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.docx"><alt-text>Multimedia component 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="dfig1"><caption><title>Supplemental Fig. 1</title><p>Consort Diagram.</p></caption><media xlink:href="mmcfigs1.jpg"><alt-text>Supplemental Fig. 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="dfig2"><caption><title>Supplementary Fig. 2</title><p>Kaplan-Meier analysis of progression-free survival 2 per RECIST version 1.1 by PD-L1 TPS (A), and overall survival by PD-L1 TPS (B).</p><p>Foot notes: PD-L1, Programmed death ligand 1; TPS, Tumor proportion score</p></caption><media xlink:href="mmcfigs2.jpg"><alt-text>Supplementary Fig. 2</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="dfig3"><caption><title>Supplementary Fig. 3</title><p>Relative fold-change (Y axis) in plasma cytokines and chemokines across treatment times [pretreatment (Pre-Tx), chemotherapy cycle 3 day 1 (C3D1), post-treatment follow-up (Post-Tx)] (X axis) and in relation to months (&lt;3, 3-6, &gt;6) of progression free survival (PFS). Numbers along the x-axis represent number of samples from each group available for analysis.</p></caption><media xlink:href="mmcfigs3.jpg"><alt-text>Supplementary Fig. 3</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="dfig4"><caption><title>Supplementary Fig. 4</title><p>Relative fold-change (Y axis) in plasma total iron (Iron), circulating ferritin (Ferritin), transferrin saturation (Iron Saturation), circulating transferrin (Transferrin), total iron binding capacity, and oxidative damage markers (immunoreactive protein carbonyls (Carbonyl), 4-hydroxynonenal-modified proteins (4HNE), and 3-nitrotyrosine (3NT) across treatment times [pretreatment (Pre-Tx), chemotherapy cycle 3 day 1 (C3D1), post-treatment follow up (Post- Tx)] (X axis) and in relation to months (&lt;3, 3-6, &gt;6) of progression free survival (PFS). Numbers along the x-axis represent numbers of samples from each group available for analysis.</p></caption><media xlink:href="mmcfigs4.jpg"><alt-text>Supplementary Fig. 4</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="dfig5"><caption><title>Supplementary Fig. 5</title><p>Relative fold-change (Y axis) in select peripheral blood mononuclear cell populations across treatment times [pretreatment (Pre-Tx), chemotherapy cycle 3 day 1(C3D1), post-treatment follow up (Post-Tx)] (X axis) and in relation to months (&lt;6, &gt; 6) of progression free survival (PFS). Numbers along x-axis represent number of samples from each group available for analysis. Treg - T-regulatory lymphocytes; CD4, CD8 - total T lymphocytes subtypes (activated effectors separated).</p></caption><media xlink:href="mmcfigs5.jpg"><alt-text>Supplementary Fig. 5</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="dfig6"><caption><title>Supplementary Fig. 6</title><p>A-F: Patient reported Quality of Life on select FACT Sub-Scales during treatment and in relation to response to therapy. Foot Note: CI - confidence Interval; C - Cycle; D - Day; FACT - Functional Assessment of Cancer Therapy; G - General; L - Lung; PR - Partial response; SD - Stable disease; PD - Progression of disease.</p></caption><media xlink:href="mmcfigs6.jpg"><alt-text>Supplementary Fig. 6</alt-text></media></supplementary-material></p>
            </sec>
            <ack id="ack0010">
              <title>Acknowledgements</title>
              <p id="p0205">We acknowledge the work of Kristina K. Greiner and Gareth R. Smith. Kristina helped in editing and proof reading of the manuscript. Gareth Smith also helped with figures and graphics.</p>
            </ack>
            <fn-group>
              <fn id="appsec2" fn-type="supplementary-material">
                <label>Appendix A</label>
                <p id="p0215">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.redox.2022.102318" id="intref0015">https://doi.org/10.1016/j.redox.2022.102318</ext-link>.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
